Core Viewpoint - BioMarin Pharmaceutical Inc. has successfully closed an offering of $850 million in senior unsecured notes to finance the acquisition of Amicus Therapeutics, Inc. and related expenses [1] Financing Details - The offering consists of 5.500% senior unsecured notes due in 2034, priced at 100.000% [1] - BioMarin plans to utilize the net proceeds from the notes, along with $2 billion from a new senior secured term loan "B" facility and $800 million from a senior secured term loan "A" facility, to fund the acquisition [1] - Additionally, a $600 million senior secured revolving credit facility is expected to be established in connection with the acquisition [1] Acquisition Context - The gross proceeds from the notes will be held in an escrow account until the acquisition is completed [1] - If the acquisition is not finalized by December 19, 2026, BioMarin must redeem the notes at their initial issue price plus accrued interest [1] Guarantees and Covenants - The notes are guaranteed by certain subsidiaries of BioMarin, including Amicus and its subsidiaries post-acquisition [1] - The indenture governing the notes includes covenants that restrict BioMarin and its subsidiaries from incurring additional debt, paying dividends, and other financial activities without exceptions [1] Regulatory Compliance - The notes have not been registered under the Securities Act and are offered only to qualified institutional buyers or non-U.S. persons [1]

Group 1 - BioMarin Pharmaceutical Inc. is considered one of the best cheap stocks to buy currently, with Barclays initiating coverage and assigning an "Overweight" rating and a target price of $80, indicating a 41.5% upside from the current price [1][2] - Barclays highlights the company's acquisition plans and strong fundamentals as key reasons for the overweight rating [1] - BioMarin is in the process of acquiring Amicus Therapeutics, Inc., and has finalized a $2 billion senior secured term loan B to fund this acquisition, alongside an $800 million loan and a $600 million revolving credit line [2] Group 2 - Among analysts covering BioMarin, 21 out of 27 (approximately 78%) have a "Buy" rating, while the remaining 6 (around 22%) recommend a "Hold" [2] - The median target price for BioMarin is $96.50, with a high estimate of $122, suggesting an upside of 70.68% (or 115.78% based on the highest estimate) [2] - BioMarin Pharmaceutical Inc. is a global biotech company focused on rare genetic diseases, founded in 1997 and headquartered in San Rafael, California [2]

Core Viewpoint - BioMarin Pharmaceutical Inc. is raising $850 million through the issuance of senior unsecured notes to finance its acquisition of Amicus Therapeutics, Inc. and related expenses [1][2][3] Financing Details - The company priced its offering of $850 million of 5.500% senior unsecured notes due in 2034 at an issue price of 100.000% [1] - BioMarin completed the syndication of a new $2 billion senior secured term loan "B" facility, in addition to an existing $800 million senior secured term loan "A" facility and a $600 million senior secured revolving credit facility [2] - The net proceeds from the notes offering, along with borrowings from the term facilities and cash on hand, will be used to fund the acquisition and related fees [3] Redemption and Guarantees - Gross proceeds from the notes will be held in an escrow account until the acquisition is completed; if not completed by December 19, 2026, the notes will be redeemed at 100% of the initial issue price plus accrued interest [4] - The notes will be jointly and severally guaranteed by certain subsidiaries of BioMarin, including Amicus and its subsidiaries after the acquisition [5] Covenants and Restrictions - The indenture governing the notes will include customary covenants that restrict BioMarin and its subsidiaries from incurring additional debt, paying dividends, and other specified actions [6] Company Overview - BioMarin is a global biotechnology company focused on rare diseases, with a strong track record of innovation and a robust pipeline of therapies [9][10]

Core Viewpoint - BioMarin Pharmaceutical Inc. is planning to raise $850 million through the issuance of senior unsecured notes due in 2034 to finance its acquisition of Amicus Therapeutics, Inc. and related expenses [1][3]. Financing Details - The company is launching a $2 billion senior secured term loan "B" facility in addition to an existing $800 million senior secured term loan "A" facility and a $600 million senior secured revolving credit facility to support the acquisition [2]. - The net proceeds from the notes offering, along with borrowings from the term facilities and cash on hand, will be used to fund the acquisition and associated fees [3]. Redemption Conditions - Gross proceeds from the notes will be held in an escrow account until the acquisition is completed, with a mandatory redemption clause if the acquisition is not finalized by December 19, 2026 [4]. Guarantees and Covenants - The notes will be guaranteed by certain subsidiaries of BioMarin, including Amicus post-acquisition, and will include customary covenants that restrict additional debt incurrence and other financial activities [5][6]. Regulatory Information - The notes will not be registered under the Securities Act and will be offered only to qualified institutional buyers or non-U.S. persons, subject to transfer restrictions [7]. Company Overview - BioMarin is a global biotechnology company focused on rare diseases, with a strong portfolio of commercial therapies and a robust pipeline for drug development [9][10].

Group 1 - The article does not contain any relevant content regarding company or industry insights [1]

Core Insights - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 250 points on Friday [1] - Carnival PLC reported better-than-expected fourth-quarter adjusted EPS results and provided FY26 adjusted EPS guidance above estimates, leading to a 16.3% increase in its shares to $30.61 [1] Company Performance - NovaBay Pharmaceuticals Inc saw a significant share price increase of 45.1%, reaching $4.28 [2] - Intuitive Machines Inc gained 31.9%, closing at $14.31 after Keybanc initiated coverage with an Overweight rating and a $20 price target [2] - Amicus Therapeutics, Inc. jumped 30.6% to $14.22 following the announcement of its acquisition by BioMarin Pharmaceutical Inc, which gained 20.4% to $62.52, with the acquisition valued at approximately $4.8 billion [2] - CoreWeave Inc surged 19.7% to $81.07 after joining the Department of Energy's Genesis Mission [2] - Firefly Aerospace Inc increased by 18.8% to $23.84 after receiving a Sector Weight rating from Keybanc [2] - Rezolve AI PLC rose 18.6% to $2.61, with a Buy rating and a $10 price target reiterated by HC Wainwright & Co. [2] - Evommune Inc surged 15.8% to $17.38 [2] - Edgewise Therapeutics Inc gained 13.7% to $24.05 [2] - Centrus Energy Corp increased by 13.4% to $260.56 [2] - Applied Digital Corp jumped 12.2% to $26.81 [2] - Bloom Energy Corp rose 11.4% to $89.40 [2] - Planet Labs PBC increased by 11.4% to $19.48 [2] - Mirum Pharmaceuticals Inc saw a 10.7% increase to $77.92 after announcing a $68.5 million private placement agreement [2] - Trump Media & Technology Group Corp surged 10.7% to $16.45 [2] - Rivian Automotive Inc gained 9.6% to $22.24, with an Outperform rating maintained and the price target raised from $16 to $25 by Wedbush [2] - Moderna Inc rose 9.2% to $33.79, with CEPI investing up to $54.3 million to advance its H5 pandemic influenza vaccine candidate [2]